What Is Tirzepatide? Understanding Mounjaro, Zepbound & the Dual-Action GLP-1

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide activates both GIP and GLP-1 receptors simultaneously, producing enhanced metabolic effects.

The medication is sold under two brand names. Mounjaro was approved by the FDA in May 2022 for the treatment of type 2 diabetes. Zepbound received FDA approval in November 2023 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

Tirzepatide is administered as a once-weekly subcutaneous injection and is available in multiple dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The dual-action mechanism has led some researchers to describe tirzepatide as the most effective anti-obesity medication available, based on head-to-head comparisons and clinical trial data.

The innovation behind tirzepatide lies in its dual receptor activation. GLP-1 receptor agonism provides the appetite-suppressing and blood-sugar-lowering effects that are well established with medications like semaglutide. GIP receptor agonism adds an additional layer of metabolic benefit that enhances overall efficacy.

GIP (glucose-dependent insulinotropic polypeptide) is a hormone released from the small intestine after eating. It plays a key role in insulin secretion, fat metabolism, and energy balance. By activating GIP receptors, tirzepatide enhances insulin sensitivity in fat tissue, promotes more efficient fat burning, and may have direct effects on the brain's appetite regulation centers that complement GLP-1 signaling.

The combined activation of both pathways produces a synergistic effect. Preclinical studies suggest the dual mechanism leads to greater reductions in body fat percentage, improved lipid profiles, and more significant reductions in liver fat compared to GLP-1-only medications. This may explain why tirzepatide consistently produces greater weight loss in clinical trials.

The SURMOUNT clinical trial program evaluated tirzepatide for weight management in over 5,000 participants. In the SURMOUNT-1 trial, participants receiving the highest dose (15 mg) lost an average of 22.5% of their body weight over 72 weeks — roughly one-quarter of their starting weight. Even the lowest dose (5 mg) produced an average weight loss of 15%.

These results surpass those seen with semaglutide in comparable trials. The SURMOUNT-2 trial, which focused on patients with both obesity and type 2 diabetes, showed average weight loss of 14.7% at the highest dose, along with A1C reductions of up to 2.4 percentage points.

A notable finding was the proportion of participants achieving clinically meaningful weight loss thresholds. In SURMOUNT-1, 63% of participants on the 15 mg dose lost at least 20% of their body weight, and 36% lost at least 25%. These numbers represent the most impressive results ever recorded for a pharmaceutical weight loss intervention in randomized controlled trials.

Tirzepatide follows a gradual dose escalation to improve tolerability. Treatment begins at 2.5 mg weekly for four weeks, then increases to 5 mg. From there, increases of 2.5 mg can occur every four weeks based on individual response and tolerability, up to a maximum of 15 mg per week.

The injection is given once weekly using a single-dose prefilled pen. Common injection sites include the abdomen, thigh, or upper arm. Patients can rotate injection sites and choose any day of the week, as long as they maintain a consistent schedule. Most patients find the injection process quick and straightforward.

Appetite reduction typically begins within the first few weeks of treatment, even at the lowest dose. Clinically significant weight loss (5% or more of body weight) is usually achieved within the first two to three months. Peak weight loss generally occurs between 12 and 18 months. As with all GLP-1 medications, tirzepatide works best when combined with dietary modifications and regular physical activity.

Brand-name tirzepatide (Zepbound) carries a list price of approximately $1,060 per month. Mounjaro, the diabetes-indicated version, costs around $1,000 per month at retail. Compounded tirzepatide is available through licensed pharmacies at lower price points, typically ranging from $300 to $500 per month.

Insurance coverage for tirzepatide is expanding but remains inconsistent. Most commercial plans cover Mounjaro for type 2 diabetes with prior authorization. Coverage for Zepbound (weight management) is more limited, though employer-sponsored plans are increasingly adding it. Eli Lilly offers a savings card program that can reduce out-of-pocket costs for eligible commercially insured patients.

At Weight Method, tirzepatide subscriptions start at $349 per month, including medication, physician oversight, and ongoing clinical support. Our medical team evaluates your health profile, BMI, and treatment goals to determine whether tirzepatide is the right choice for you.